CN1235568C - 水基药物组合物 - Google Patents
水基药物组合物 Download PDFInfo
- Publication number
- CN1235568C CN1235568C CNB971974799A CN97197479A CN1235568C CN 1235568 C CN1235568 C CN 1235568C CN B971974799 A CNB971974799 A CN B971974799A CN 97197479 A CN97197479 A CN 97197479A CN 1235568 C CN1235568 C CN 1235568C
- Authority
- CN
- China
- Prior art keywords
- compositions
- composition
- active substance
- viscosity
- nasal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 217
- 239000003814 drug Substances 0.000 claims abstract description 117
- 210000003928 nasal cavity Anatomy 0.000 claims abstract description 39
- 239000002245 particle Substances 0.000 claims abstract description 32
- 239000000375 suspending agent Substances 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 19
- 239000007787 solid Substances 0.000 claims abstract description 18
- 230000009974 thixotropic effect Effects 0.000 claims abstract description 12
- 238000005507 spraying Methods 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000000725 suspension Substances 0.000 claims description 22
- 241000158526 Nasalis Species 0.000 claims description 20
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 19
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 18
- 239000002270 dispersing agent Substances 0.000 claims description 16
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- 210000001331 nose Anatomy 0.000 claims description 14
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 13
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 13
- 239000012528 membrane Substances 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 12
- 210000004086 maxillary sinus Anatomy 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 11
- 230000003637 steroidlike Effects 0.000 claims description 11
- 210000001944 turbinate Anatomy 0.000 claims description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 9
- 230000000845 anti-microbial effect Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 238000010008 shearing Methods 0.000 claims description 9
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 230000000420 mucociliary effect Effects 0.000 claims description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 239000000499 gel Substances 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 230000009967 tasteless effect Effects 0.000 claims description 5
- 201000010105 allergic rhinitis Diseases 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 229920000136 polysorbate Polymers 0.000 claims description 3
- 239000003380 propellant Substances 0.000 claims description 3
- 230000000284 resting effect Effects 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 16
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 239000011149 active material Substances 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 239000003595 mist Substances 0.000 abstract description 3
- 239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 abstract 1
- 230000009965 odorless effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 230000003203 everyday effect Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 210000002850 nasal mucosa Anatomy 0.000 description 5
- 238000005259 measurement Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 210000003695 paranasal sinus Anatomy 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000909851 Epiphora Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000013572 airborne allergen Substances 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960000800 cetrimonium bromide Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000016747 lacrimal apparatus disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
- B05B11/1001—Piston pumps
- B05B11/1016—Piston pumps the outlet valve having a valve seat located downstream a movable valve element controlled by a pressure actuated controlling element
- B05B11/1018—Piston pumps the outlet valve having a valve seat located downstream a movable valve element controlled by a pressure actuated controlling element and the controlling element cooperating with means for opening or closing the inlet valve
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
成分 | 重量百分比 | 用量,mg |
曲安奈德,USP局部微粉级(micronized topical grade)(TAA) | 0.055 | 9.075 |
微晶纤维素和羧甲基纤维素钠的混合物,NF | 2.0 | 330.00 |
Polysorbate 80,NF表面活性剂 | 0.004 | 0.66 |
乙二胺四乙酸二钠,USP | 0.05 | 8.25 |
苯扎氯铵(BzCl)溶液50wt.%的BzCl,NF | 0.03 | 4.95 |
葡萄糖(无水),USP | 5.0 | 825.00 |
纯净水,USP | 92.86 | 15.322 |
稀盐酸,NF | * | * |
0.1N的氢氧化钠溶液 | * | * |
总重量 | 16.5g |
Claims (32)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/678,465 US5976573A (en) | 1996-07-03 | 1996-07-03 | Aqueous-based pharmaceutical composition |
US08/678,465 | 1996-07-03 | ||
US08/678465 | 1996-07-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1228712A CN1228712A (zh) | 1999-09-15 |
CN1235568C true CN1235568C (zh) | 2006-01-11 |
Family
ID=24722901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB971974799A Expired - Lifetime CN1235568C (zh) | 1996-07-03 | 1997-07-02 | 水基药物组合物 |
Country Status (27)
Country | Link |
---|---|
US (8) | US5976573A (zh) |
EP (2) | EP1382330A1 (zh) |
JP (1) | JP2001501914A (zh) |
KR (1) | KR100383601B1 (zh) |
CN (1) | CN1235568C (zh) |
AP (1) | AP1045A (zh) |
AT (1) | ATE250432T1 (zh) |
AU (1) | AU737506C (zh) |
BG (1) | BG64585B1 (zh) |
BR (1) | BR9710115B1 (zh) |
CA (1) | CA2268927C (zh) |
CZ (1) | CZ299689B6 (zh) |
DE (1) | DE69725161T2 (zh) |
DK (1) | DK0938345T3 (zh) |
EA (1) | EA001406B1 (zh) |
ES (1) | ES2208931T3 (zh) |
HK (1) | HK1022652A1 (zh) |
HU (1) | HU227993B1 (zh) |
IL (1) | IL127611A0 (zh) |
NO (1) | NO318241B1 (zh) |
OA (1) | OA10950A (zh) |
PL (1) | PL194269B1 (zh) |
PT (1) | PT938345E (zh) |
SK (1) | SK284491B6 (zh) |
UA (1) | UA68337C2 (zh) |
WO (1) | WO1998000178A1 (zh) |
ZA (1) | ZA975947B (zh) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
US20030215396A1 (en) * | 1999-09-15 | 2003-11-20 | Boehringer Ingelheim Pharma Kg | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
GB9701552D0 (en) * | 1997-01-25 | 1997-03-12 | Bristol Myers Squibb Co | Multi-dose wound gel |
US20050163719A1 (en) * | 1997-10-01 | 2005-07-28 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing diazepam |
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
US20040141923A1 (en) * | 1997-10-01 | 2004-07-22 | Dugger Harry A. | Buccal, polar and non-polar spray containing alprazolam |
US20030190286A1 (en) * | 1997-10-01 | 2003-10-09 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
US20040136913A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing sumatriptan |
US20030095925A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
US20040136914A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing ondansetron |
US20040136915A1 (en) * | 1997-10-01 | 2004-07-15 | Dugger Harry A. | Buccal, polar and non-polar spray containing atropine |
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20050180923A1 (en) * | 1997-10-01 | 2005-08-18 | Dugger Harry A.Iii | Buccal, polar and non-polar spray containing testosterone |
US20050287075A1 (en) * | 1997-10-01 | 2005-12-29 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US20030185761A1 (en) * | 1997-10-01 | 2003-10-02 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating pain |
US7632517B2 (en) * | 1997-10-01 | 2009-12-15 | Novadel Pharma Inc. | Buccal, polar and non-polar spray containing zolpidem |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
AU4894697A (en) * | 1997-10-01 | 1999-04-23 | Flemington Pharmaceutical Corporation | Buccal, polar and non-polar spray or capsule |
US20050002867A1 (en) * | 1997-10-01 | 2005-01-06 | Novadel Pharma Inc. | Buccal, polar and non-polar sprays containing propofol |
US20030077228A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders |
US20030095927A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
TWI243687B (en) * | 1998-04-21 | 2005-11-21 | Teijin Ltd | Pharmaceutical composition for application to mucosa |
US20020061281A1 (en) * | 1999-07-06 | 2002-05-23 | Osbakken Robert S. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
US6576224B1 (en) * | 1999-07-06 | 2003-06-10 | Sinuspharma, Inc. | Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis |
AR026073A1 (es) | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica acuosa que contiene ciclesonida |
US6565832B1 (en) * | 2000-01-31 | 2003-05-20 | Schering-Plough Healthcare Products, Inc. | Spray composition with reduced dripping |
US20020013331A1 (en) | 2000-06-26 | 2002-01-31 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
US20030072717A1 (en) * | 2001-02-23 | 2003-04-17 | Vapotronics, Inc. | Inhalation device having an optimized air flow path |
AU2002310054B2 (en) * | 2001-05-21 | 2007-02-01 | Injet Digital Aerosols Limited | Compositions for protein delivery via the pulmonary route |
BG65734B1 (bg) * | 2002-02-22 | 2009-09-30 | Био Терапютикс - Еоод | Течен мукоадхезивен фармацевтичен състав |
US6641799B2 (en) | 2002-04-03 | 2003-11-04 | Nos Spray, Inc. | Nasal spray for decongesting nasal passages |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
EP1374856A1 (en) * | 2002-06-18 | 2004-01-02 | Impetus AG | Oily thixotropic nasal spray |
US20040023935A1 (en) * | 2002-08-02 | 2004-02-05 | Dey, L.P. | Inhalation compositions, methods of use thereof, and process for preparation of same |
WO2004024187A2 (en) * | 2002-09-13 | 2004-03-25 | Zicam, Llc. | Compositions to reduce congestion and methods for application thereof to the nasal membrane |
JP2006508138A (ja) * | 2002-11-12 | 2006-03-09 | アルコン,インコーポレイテッド | アレルギー性鼻炎を処置するための抗アレルギー剤およびステロイドの使用 |
US20040109826A1 (en) * | 2002-12-06 | 2004-06-10 | Dey, L.P. | Stabilized albuterol compositions and method of preparation thereof |
CA2509775C (en) * | 2003-01-13 | 2010-06-01 | The Procter & Gamble Company | Compositions for prevention and treatment of cold and influenza-like symptoms comprising select mucoadhesive polymers |
US7811606B2 (en) * | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
US9808471B2 (en) * | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
US8912174B2 (en) | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
CA2537185A1 (en) * | 2003-08-29 | 2005-03-10 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv |
US20050058673A1 (en) | 2003-09-09 | 2005-03-17 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
EP1694655A2 (en) * | 2003-11-26 | 2006-08-30 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
WO2005065185A2 (en) * | 2003-12-24 | 2005-07-21 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
US7361168B2 (en) | 2004-04-21 | 2008-04-22 | Acclarent, Inc. | Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders |
SE0401031D0 (sv) | 2004-04-22 | 2004-04-22 | Duocort Ab | A new glucocorticoid replacement therapy |
US9028852B2 (en) * | 2004-09-07 | 2015-05-12 | 3M Innovative Properties Company | Cationic antiseptic compositions and methods of use |
US20060051384A1 (en) * | 2004-09-07 | 2006-03-09 | 3M Innovative Properties Company | Antiseptic compositions and methods of use |
US8198326B2 (en) * | 2004-09-07 | 2012-06-12 | 3M Innovative Properties Company | Phenolic antiseptic compositions and methods of use |
PL1814538T3 (pl) * | 2004-11-24 | 2010-02-26 | Alcon Inc | Sposób dostarczania donosowego sprayu |
EP2486942B1 (en) | 2004-11-24 | 2018-10-10 | Meda Pharmaceuticals Inc. | Compositions comprising azelastine and methods of use thereof |
KR100666220B1 (ko) * | 2005-01-31 | 2007-01-09 | 영남대학교 산학협력단 | 구내염 치료용 분사제 조성물 |
KR20070113281A (ko) * | 2005-03-10 | 2007-11-28 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 항미생물성 조성물 및 방법 |
WO2006099325A2 (en) * | 2005-03-10 | 2006-09-21 | 3M Innovative Properties Company | Methods of treating ear infections |
WO2006099359A2 (en) * | 2005-03-10 | 2006-09-21 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
US7851419B2 (en) * | 2005-09-12 | 2010-12-14 | Nawaz Ahmad | Substantially anhydrous sprayable personal lubricant |
US20070059250A1 (en) * | 2005-09-12 | 2007-03-15 | Nawaz Ahmad | Sprayable personal lubricant |
US7915286B2 (en) | 2005-09-16 | 2011-03-29 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
RU2008119323A (ru) | 2005-10-19 | 2009-11-27 | Рэнбакси Лабораториз Лимитед (In) | Фармацевтические композиции мускаринового рецептора |
BRPI0617673C1 (pt) * | 2005-10-19 | 2012-05-22 | Ranbaxy Lab Ltd | composições de inibidores de fosfodiesterase do tipo iv |
US8497258B2 (en) * | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
US20070231396A1 (en) * | 2006-03-29 | 2007-10-04 | Ray Charles D | Medication spray formulation |
US20100029728A1 (en) * | 2006-09-22 | 2010-02-04 | Ranbaxy Laboratories Limited | Phosphodiesterase inhibitors |
EA200900472A1 (ru) * | 2006-09-22 | 2009-10-30 | Ранбакси Лабораторис Лимитед | Ингибиторы фосфодиэстеразы iv типа |
US8338491B2 (en) | 2006-10-27 | 2012-12-25 | 3M Innovative Properties Company | Antimicrobial compositions |
EP1958947A1 (en) | 2007-02-15 | 2008-08-20 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type 4 |
KR20080076667A (ko) * | 2007-02-15 | 2008-08-20 | 주식회사 중외제약 | 요변성 약학 조성물 |
EP2124944B1 (en) * | 2007-03-14 | 2012-02-15 | Ranbaxy Laboratories Limited | Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors |
EP2124943A1 (en) * | 2007-03-14 | 2009-12-02 | Ranbaxy Laboratories Limited | Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors |
AU2008251370A1 (en) * | 2007-05-10 | 2008-11-20 | Novadel Pharma Inc. | Anti-insomnia compositions and methods |
EP2111861A1 (en) | 2008-04-21 | 2009-10-28 | Ranbaxy Laboratories Limited | Compositions of phosphodiesterase type IV inhibitors |
WO2010052575A2 (en) | 2008-11-10 | 2010-05-14 | Scandivir Ab | Ngna compositions and methods of use |
US9629868B2 (en) | 2009-04-06 | 2017-04-25 | Joshua D. Levine | Method of treating and preventing neuro-olfactory triggered or aggravated illnesses or related conditions |
US10350233B2 (en) | 2009-04-06 | 2019-07-16 | Joshua D. Levine | Method of treating and preventing neuro-olfactory triggered or aggravated illnesses or related conditions |
US8439896B2 (en) * | 2009-11-13 | 2013-05-14 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
US8894630B2 (en) | 2009-11-13 | 2014-11-25 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
US8888761B2 (en) * | 2009-11-13 | 2014-11-18 | The Invention Science Fund I, Llc | Device, system, and method for targeted delivery of anti-inflammatory medicaments to a mammalian subject |
US20120000941A1 (en) * | 2010-06-30 | 2012-01-05 | Inspire Pharmaceuticals, Inc. | Medicine dispenser |
EP3520749A1 (en) | 2010-10-15 | 2019-08-07 | Clearside Biomedical, Inc. | Device for ocular access |
BR112013017183A2 (pt) * | 2011-01-04 | 2017-07-25 | Bausch & Lomb | composições de bepostatina |
FR2970180B1 (fr) | 2011-01-06 | 2013-08-02 | Substipharm Dev | Procede de preparation de suspensions aqueuses pharmaceutiques comprenant un medicament efficace dans le traitement des rhinites |
US9181185B2 (en) | 2011-10-31 | 2015-11-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
BR112015010566A2 (pt) * | 2012-11-08 | 2017-07-11 | Clearside Biomedical Inc | métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos |
WO2014179698A2 (en) | 2013-05-03 | 2014-11-06 | Clearside Biomedical, Inc. | Apparatus and methods for ocular injection |
US10188550B2 (en) | 2013-06-03 | 2019-01-29 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
WO2017023162A1 (en) * | 2015-08-04 | 2017-02-09 | Inqpharm Group Sdn Bhd | A nasal composition |
US20170121098A1 (en) * | 2015-11-02 | 2017-05-04 | American Sterilizer Company | Non-aspirating transport gel dispenser |
US10390901B2 (en) | 2016-02-10 | 2019-08-27 | Clearside Biomedical, Inc. | Ocular injection kit, packaging, and methods of use |
WO2017192565A1 (en) | 2016-05-02 | 2017-11-09 | Clearside Biomedical, Inc. | Systems and methods for ocular drug delivery |
IL264764B2 (en) | 2016-08-12 | 2024-02-01 | Clearside Biomedical Inc | Devices and methods for adjusting the insertion depth of a drug administration needle |
EP3694524A1 (en) | 2017-10-11 | 2020-08-19 | Lifescience AS | N-acetylneuraminic acid compositions and methods of use |
HRP20211996T1 (hr) | 2018-09-11 | 2022-04-01 | Lead Biotherapeutics Ltd. | Sustav mukoadhezivne disperzijske nanočestice i metoda proizvodnje istog |
CN115461057A (zh) | 2020-04-01 | 2022-12-09 | 生命科学股份有限公司 | 用于抑制和治疗冠状病毒感染的唾液酸组合物 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2156254A (en) * | 1937-10-29 | 1939-04-25 | Piedmont Dev Corp | Therapeutic composition |
US2186254A (en) * | 1939-03-31 | 1940-01-09 | Westinghouse Electric & Mfg Co | Multispeed motor control |
US3035984A (en) * | 1958-08-26 | 1962-05-22 | Wallace & Tiernan Inc | Dihydrocodeinone resin complex suspensions |
US3035064A (en) * | 1958-10-15 | 1962-05-15 | Roussel Uclaf | 18-11 lactone of 3-oxygenated 11beta-hydroxy-13, 17-seco-etiocholane-17, 18-dioic acid and its esters and processes for their production |
US3829794A (en) * | 1971-03-04 | 1974-08-13 | Lambda Electronics Corp | Circuit for reducing the direct current component of an alternating current output signal |
US3780176A (en) * | 1971-10-05 | 1973-12-18 | American Cyanamid Co | Predominantly aqueous substituted triamcinolone compositions |
US3809294A (en) * | 1973-06-27 | 1974-05-07 | American Cyanamid Co | Dispensing lung contacting powdered medicaments |
US3895111A (en) * | 1973-06-27 | 1975-07-15 | American Cyanamid Co | Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate |
US4933168A (en) * | 1975-05-27 | 1990-06-12 | Syntex Pharmaceuticals International Limited | Stable, crystalline flunisolide |
US4405598A (en) * | 1976-01-30 | 1983-09-20 | Fisons, Limited | Composition for treating asthma |
GB2042888B (en) * | 1979-03-05 | 1983-09-28 | Teijin Ltd | Preparation for administration to the mucosa of the oral or nasal cavity |
US4280163A (en) * | 1979-03-05 | 1981-07-21 | Homexx International Corp. | Electronic lock |
US4407792A (en) * | 1979-05-09 | 1983-10-04 | Alcon Laboratories, Inc. | Sustained release ophthalmic drug dosage |
JPS6034925B2 (ja) * | 1979-07-31 | 1985-08-12 | 帝人株式会社 | 持続性鼻腔用製剤およびその製造法 |
PH24267A (en) * | 1980-02-15 | 1990-05-29 | Glaxo Group Ltd | Androstane carbothioates and pharmaceutical compositions containing the same |
US4304765A (en) * | 1980-10-14 | 1981-12-08 | Alza Corporation | Ocular insert housing steroid in two different therapeutic forms |
DE3046584C2 (de) * | 1980-12-11 | 1984-03-15 | Dr.-Ing. Rudolf Hell Gmbh, 2300 Kiel | Optisch-mechanischer Abtaster |
IT1194068B (it) * | 1981-05-20 | 1988-09-14 | Getters Spa | Linguetta di supporto perfezionata per dispositivi getter |
EP0073357A3 (en) | 1981-08-19 | 1984-02-22 | NESPAK S.p.A. Società Generale per L'Imballaggio | Assemblable and stackable crate of plastic material and apparatus for assembling same |
US4432964A (en) * | 1981-08-24 | 1984-02-21 | Alza Corporation | Topical composition containing steroid in two forms released independently from polymeric carrier |
US4443440A (en) * | 1982-08-30 | 1984-04-17 | The Upjohn Company | Amine containing ester prodrugs of corticosteroids |
US4427681A (en) * | 1982-09-16 | 1984-01-24 | Richardson-Vicks, Inc. | Thixotropic compositions easily convertible to pourable liquids |
US4478818A (en) * | 1982-12-27 | 1984-10-23 | Alza Corporation | Ocular preparation housing steroid in two different therapeutic forms |
FR2546407B1 (fr) * | 1983-05-24 | 1986-04-18 | Therapeutique Applic Sa | Medicament a activite anti-allergique pour administration locale a base d'acide n-acetyl(a,b)-aspartyl glutamique |
JPS6032714A (ja) * | 1983-08-01 | 1985-02-19 | Teijin Ltd | 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 |
EP0187433B1 (en) * | 1983-08-01 | 1990-12-27 | Teijin Limited | Powdery pharmaceutical composition suitable for application to mucosa of oral or nasal cavity |
US4782047A (en) * | 1986-05-22 | 1988-11-01 | Syntex Pharmaceuticals International Ltd. | Aqueous steroid formulations for nasal administration |
US4983595A (en) * | 1986-05-22 | 1991-01-08 | Syntex (U.S.A.) Inc. | Aqueous steroid formulations for nasal administration |
EP0279121B1 (en) * | 1986-12-23 | 1993-09-01 | FISONS plc | Pharmaceutical compositions comprising an aqueous solution of a pyranoquinoline derivative |
US4767612A (en) * | 1987-01-23 | 1988-08-30 | Rorer Pharmaceutical Corporation | Triamcinolone acetonide for the treatment of allergic rhinitis |
DE3877904D1 (de) * | 1987-11-13 | 1993-03-11 | Asta Pharma Ag | Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge. |
JPH01294620A (ja) | 1988-05-19 | 1989-11-28 | Kissei Pharmaceut Co Ltd | 水溶液製剤およびその製造方法 |
JP2546347B2 (ja) * | 1988-08-15 | 1996-10-23 | 日本電気株式会社 | 無線送受信装置 |
US5461081A (en) * | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
US5439670A (en) * | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
US5124154A (en) * | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
WO1992004365A1 (en) | 1990-09-10 | 1992-03-19 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
US5300302A (en) * | 1990-10-04 | 1994-04-05 | Nestec S.A. | Pharmaceutical composition in gel form in a dispensing package |
SE9003712L (sv) * | 1990-11-22 | 1992-01-07 | Kabi Pharmacia Ab | Gelbildande flytande baerarkomposition samt anvaendning daerav i farmaceutiska kompositioner |
GB9102579D0 (en) * | 1991-01-24 | 1991-03-27 | Glaxo Group Ltd | Compositions |
GB9103824D0 (en) * | 1991-02-23 | 1991-04-10 | Fisons Ag | Formulation |
CA2455115C (en) | 1991-12-12 | 2008-05-27 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
DE4221256C2 (de) | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenische Zusammensetzung für die topische Anwendung |
GB9218834D0 (en) * | 1992-09-05 | 1992-10-21 | Procter & Gamble | Nasal spray products |
US5429824A (en) * | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
TW401300B (en) * | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
US5425952A (en) * | 1993-10-13 | 1995-06-20 | Church & Dwight Co., Inc. | Slow-release ammonium bicarbonate fungicide compositions |
US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
JP3021312B2 (ja) | 1994-03-15 | 2000-03-15 | 千寿製薬株式会社 | プラノプロフェンの安定化方法および安定なプラノプロフェン水性液剤 |
US5389386A (en) * | 1994-06-30 | 1995-02-14 | Church & Dwight Co., Inc. | Method of controlling fungal disease in cultivated plants |
NZ298169A (en) | 1994-12-22 | 1999-09-29 | Astra Ab | Aerosol drug formulation; comprises hydrofluoroalkane propellant, medicament for inhalation and a surfactant |
IT1275955B1 (it) * | 1995-03-22 | 1997-10-24 | Dompe Spa | Formulazioni farmaceutiche in forma di gel tissotropico |
EP0780127A1 (en) * | 1995-12-19 | 1997-06-25 | The Procter & Gamble Company | A nasal spray containing a steroid and a antihistamine |
EP0954318A1 (en) * | 1996-06-04 | 1999-11-10 | The Procter & Gamble Company | A nasal spray containing an intranasal steroid and an antihistamine |
US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
-
1996
- 1996-07-03 US US08/678,465 patent/US5976573A/en not_active Expired - Lifetime
-
1997
- 1997-02-07 UA UA99020608A patent/UA68337C2/uk unknown
- 1997-07-02 BR BRPI9710115-0A patent/BR9710115B1/pt not_active IP Right Cessation
- 1997-07-02 KR KR10-1999-7000006A patent/KR100383601B1/ko not_active IP Right Cessation
- 1997-07-02 SK SK1816-98A patent/SK284491B6/sk not_active IP Right Cessation
- 1997-07-02 CN CNB971974799A patent/CN1235568C/zh not_active Expired - Lifetime
- 1997-07-02 PT PT97933237T patent/PT938345E/pt unknown
- 1997-07-02 WO PCT/US1997/011462 patent/WO1998000178A1/en active IP Right Grant
- 1997-07-02 JP JP10504409A patent/JP2001501914A/ja not_active Withdrawn
- 1997-07-02 IL IL12761197A patent/IL127611A0/xx not_active IP Right Cessation
- 1997-07-02 PL PL97330936A patent/PL194269B1/pl not_active IP Right Cessation
- 1997-07-02 AU AU36471/97A patent/AU737506C/en not_active Expired
- 1997-07-02 EP EP03077914A patent/EP1382330A1/en not_active Withdrawn
- 1997-07-02 CA CA002268927A patent/CA2268927C/en not_active Expired - Fee Related
- 1997-07-02 AP APAP/P/1999/001495A patent/AP1045A/en active
- 1997-07-02 EP EP97933237A patent/EP0938345B1/en not_active Expired - Lifetime
- 1997-07-02 DK DK97933237T patent/DK0938345T3/da active
- 1997-07-02 CZ CZ0437798A patent/CZ299689B6/cs not_active IP Right Cessation
- 1997-07-02 AT AT97933237T patent/ATE250432T1/de active
- 1997-07-02 HU HU9903503A patent/HU227993B1/hu unknown
- 1997-07-02 EA EA199900080A patent/EA001406B1/ru not_active IP Right Cessation
- 1997-07-02 ES ES97933237T patent/ES2208931T3/es not_active Expired - Lifetime
- 1997-07-02 DE DE69725161T patent/DE69725161T2/de not_active Expired - Lifetime
- 1997-07-03 ZA ZA9705947A patent/ZA975947B/xx unknown
-
1998
- 1998-12-21 NO NO19986023A patent/NO318241B1/no not_active IP Right Cessation
- 1998-12-31 OA OA9800254A patent/OA10950A/en unknown
-
1999
- 1999-01-28 BG BG103127A patent/BG64585B1/bg unknown
- 1999-05-20 US US09/315,454 patent/US6143329A/en not_active Expired - Lifetime
-
2000
- 2000-03-13 HK HK00101538A patent/HK1022652A1/xx not_active IP Right Cessation
- 2000-04-28 US US09/561,371 patent/US6375984B1/en not_active Expired - Lifetime
-
2002
- 2002-04-23 US US10/128,154 patent/US7122206B2/en not_active Expired - Fee Related
-
2006
- 2006-10-16 US US11/581,565 patent/US20070031887A1/en not_active Abandoned
-
2008
- 2008-07-08 US US12/217,691 patent/US20090124586A1/en not_active Abandoned
-
2010
- 2010-03-22 US US12/728,984 patent/US7977045B2/en not_active Expired - Fee Related
-
2011
- 2011-05-31 US US13/149,260 patent/US20110230455A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1235568C (zh) | 水基药物组合物 | |
CN1046094C (zh) | 多糖体用于制备原位胶凝的眼科组合物的用途 | |
CN102319209B (zh) | 鼻用药物制剂和使用方法 | |
CN101394835A (zh) | 雾化剂型及其制作方法 | |
CN105434351B (zh) | 一种复方醋酸氟轻松喷雾剂及其制备方法 | |
CN1805729A (zh) | 鼻用药物制剂和使用方法 | |
CN105534792A (zh) | 一种含有纳米钻石烯的中草药牙膏 | |
EP0505374B1 (en) | Vitamin-mineral treatment methods and compositions | |
JP2005281315A6 (ja) | 水性薬理組成物 | |
JP2005281315A (ja) | 水性薬理組成物 | |
CN1879653B (zh) | 牛黄纳米粉制备工艺及其药物制剂 | |
CN1084185C (zh) | 一种治疗口腔和咽喉疾病的液体喷雾剂 | |
CN117180563A (zh) | 一种雾化给药装置 | |
JP2004196676A (ja) | 点鼻剤 | |
CN1227741A (zh) | 口洁雾及其生产工艺 | |
CN103751189A (zh) | 一种治疗鼻炎的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: AVENTIS PHARMACEUTICAL COMPANY Free format text: FORMER OWNER: EVANDIS MEDICINE STOCK CO., LTD. Effective date: 20060908 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20060908 Address after: new jersey Patentee after: Aventis Address before: The United States Delaware Patentee before: Aventis Pharmaceutical Inc. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160923 Address after: Delaware Patentee after: Aventis Saab limited liability company Address before: new jersey Patentee before: Aventis |
|
CX01 | Expiry of patent term |
Granted publication date: 20060111 |
|
CX01 | Expiry of patent term |